Word

Status

Dead

Status Code

404

Status Date

Thursday, February 15, 2018

Serial Number

79069161

Registration Number

3771814

Registration Date

Tuesday, April 6, 2010

Mark Type

2000

Filing Date

Thursday, February 14, 2008

Published for Opposition

Tuesday, January 19, 2010

Cancellation Date

Thursday, February 15, 2018

Trademark Owner History

SHIJIAZHUANG YILING PHARMACEUTICAL INC. - Original Registrant
Shijiazhuang Yiling; Pharmaceutical Co., Ltd. - Owner At Publication

Classifications

5 Pharmaceutical preparations for the treatment of cardiovascular system diseases, namely, hypertension, and heart failure; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of nutrition metabolism barrier diseases, namely, malnutrition and beriberi; Pharmaceutical preparations for the treatment of metabolism diseases, namely, diabetes, obesity, diabetic ketoacidosis, hypoxemia DKA and high fat proteinemia; Pharmaceutical preparations for the treatment of endocrine system diseases, namely, next cerebral ganglion pituitary gland sickness, thyroid gland sickness, ophoropathy and parathyroid sickness; Pharmaceutical preparations for the treatment of circulatory system diseases, namely, shock, heart valve sickness, arrhythmia, arteriosclerosis, cardiomyopathy periphery blood vessel disease, hypertensive disease and pericarditis; Pharmaceutical preparations for the treatment of respiratory disorder, namely, chronic bronchitis, bronchial asthma, disease of pulmonary circulation, pneumonia and acute trachea bronchitis; Pharmaceutical preparations for the treatment of digesting system diseases, namely, abdominal pain, constipation, diarrhea, cholecystitus, liver cirrhosis, liver function failure and gastritis; Pharmaceutical preparations for the treatment of urinary system diseases, namely, kidney stone, renal tumor, chronic kidney function failure, urinary tract infection and cystonephrosis; Pharmaceutical preparations for the treatment of hematopoietic system diseases, namely, anemia, leukemia and lymphoma; Pharmaceutical preparations for the treatment of immune system diseases, namely, serum sickness, allergic shock and allergic rhinitis; Pharmaceutical preparations for the treatment of rheumatic diseases and osteoarthritis, namely, rheumatic fever, lupus erythematosus, sjogren's syndrome, behcet disease and dermatomyositis; Pharmaceutical preparations for the treatment of nerve diseases, namely, schizophrenia and neurosis; Pharmaceutical preparations for the treatment of nervous system diseases, namely, headache, multiple sclerosis and muscle diseases; Pharmaceutical preparations for the treatment of skin diseases, namely, eczema, belt-shaped blister measles, namely, herpes zoster, connective tissue disease, lupus erythematosus and nervous dermatitis; Pharmaceutical preparations for the treatment of reproductive system inflammation, namely, pelvic inflammatory disease, cervicitis and vestibule big gland inflammation; Pharmaceutical preparations for the treatment of natural dissemination diseases, namely, gonorrhea, syphilis and AIDS; Pharmaceutical preparations for the treatment of female reproductive system tumor, namely, sarcoma uteri, carcinoma of cervix and endometrium cancer; Pharmaceutical preparations for the treatment of menopathy, namely, menopause, painful menstruation and menopause syndrome; Pharmaceutical preparations for the treatment of newborn symptom and diseases, namely, the newborn faints from fright, newborn vomit and newborn septicaemia; Pharmaceutical preparations for the treatment of surgical department conditions, namely, tetanus, wounds and tumors

Color is not claimed as a feature of the mark.
The mark consists of an oval inside of which appears a stick figure shape formed from a circle above a rectangle with rounded edges and which dissects an oval shape. The transliteration of the non-Latin characters, which appear below the design, is "YI LING", which are the Chinese characters constituting the first name of the president of the applicant. The two characters as so combined do not have any meaning in English.
The non-Latin characters in the mark transliterate to "YI LING" and this has no meaning in a foreign language.
The wording "YI LING" has no meaning in a foreign language.

Trademark Events

Aug 31, 2018

Notification Of Effect Of Cancellation Of Intl Reg E-Mailed

Aug 31, 2018

Death Of International Registration

Jan 11, 2018

Change Of Name/Address Rec'd From Ib

Aug 4, 2017

Total Invalidation Processed By The Ib

Jul 13, 2017

Generic Madrid Transaction Sent To Ib

Jul 13, 2017

Generic Madrid Transaction Created

Jul 11, 2017

Total Invalidation Of Reg Ext Protection Created

Nov 11, 2016

Cancelled Section 71

Mar 25, 2016

Teas Change Of Correspondence Received

Feb 7, 2013

Final Decision Transaction Processed By Ib

Jul 28, 2010

Final Disposition Notice Sent To Ib

Jul 28, 2010

Final Disposition Processed

Jul 7, 2010

Final Disposition Notice Created, To Be Sent To Ib

Apr 6, 2010

Registered-Principal Register

Jan 19, 2010

Official Gazette Publication Confirmation E-Mailed

Jan 19, 2010

Published For Opposition

Dec 14, 2009

Law Office Publication Review Completed

Dec 8, 2009

Approved For Pub - Principal Register

Dec 8, 2009

Examiner's Amendment Entered

Dec 8, 2009

Notification Of Examiners Amendment E-Mailed

Dec 8, 2009

Examiners Amendment E-Mailed

Dec 8, 2009

Examiners Amendment -Written

Nov 20, 2009

Correction Transaction Received From Ib

Nov 18, 2009

Teas/Email Correspondence Entered

Nov 18, 2009

Correspondence Received In Law Office

Nov 18, 2009

Assigned To Lie

Nov 5, 2009

Teas Response To Office Action Received

Nov 5, 2009

Attorney/Dom.Rep.Revoked And/Or Appointed

Nov 5, 2009

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Jul 24, 2009

Refusal Processed By Ib

Jun 30, 2009

Non-Final Action Mailed - Refusal Sent To Ib

Jun 30, 2009

Refusal Processed By Mpu

Jun 30, 2009

Non-Final Action (Ib Refusal) Prepared For Review

Jun 30, 2009

Application Filing Receipt Mailed

Jun 29, 2009

Non-Final Action Written

Jun 26, 2009

Assigned To Examiner

Jun 26, 2009

New Application Office Supplied Data Entered In Tram

Jun 25, 2009

Sn Assigned For Sect 66a Appl From Ib